US equities |
MU $937.08 ▼-5.25% META $762.85 ▲+2.68% NVDA $227.09 ▲+0.34% SNDK $1,447.82 ▼-2.66% MSFT $545.93 ▲+0.88% AAPL $342.35 ▲+0.40% SPCX $156.87 ▼-4.01% AMD $596.98 ▲+0.46%
FinancialContent

Veracyte, Inc. - Common Stock (NQ:VCYT)

43.61 -0.41 (-0.93%)
Delayed Quote Updated: 2:45 PM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
First predictive evidence in intermediate-risk prostate cancer supporting use of the Decipher test to guide short-term hormone therapy decisions to be presented at ASTRO 2026 
From Veracyte, Inc.
Via GlobeNewswire
News headline image
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
Six oral presentations and two posters will highlight Decipher’s prognostic and predictive value in identifying patients’ risk of progression and likelihood of benefiting from treatment... 
From Veracyte, Inc.
Via GlobeNewswire
News headline image
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey 
From Veracyte, Inc.
Via GlobeNewswire
News headline image
Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
From Veracyte, Inc.
Via GlobeNewswire
News headline image
Veracyte Announces Second Quarter 2026 Financial Results
From Veracyte, Inc.
Via GlobeNewswire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via GlobeNewswire
News headline image
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
From Veracyte
Via Business Wire
News headline image
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
From Veracyte, Inc.
Via Business Wire
News headline image
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
From Veracyte
Via Business Wire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech
Issued on behalf of VentriPoint Diagnostics Ltd. 
From USA News Group
Via GlobeNewswire
News headline image
Veracyte Announces First Quarter 2026 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Names Kevin Haas as Chief Development and Technology Officer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium
From Veracyte
Via Business Wire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Third Quarter 2025 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
From Veracyte, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >